QLI vs. LUMO, ONCT, ITRM, FBRX, LSTA, BIOR, LPCN, TXMD, BFRG, and GDTC
Should you be buying Qilian International Holding Group stock or one of its competitors? The main competitors of Qilian International Holding Group include Lumos Pharma (LUMO), Oncternal Therapeutics (ONCT), Iterum Therapeutics (ITRM), Forte Biosciences (FBRX), Lisata Therapeutics (LSTA), Biora Therapeutics (BIOR), Lipocine (LPCN), TherapeuticsMD (TXMD), Bullfrog AI (BFRG), and CytoMed Therapeutics (GDTC). These companies are all part of the "pharmaceutical preparations" industry.
Qilian International Holding Group (NASDAQ:QLI) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, community ranking, valuation, media sentiment, institutional ownership, risk, earnings and dividends.
In the previous week, Qilian International Holding Group had 1 more articles in the media than Lumos Pharma. MarketBeat recorded 1 mentions for Qilian International Holding Group and 0 mentions for Lumos Pharma. Qilian International Holding Group's average media sentiment score of 0.00 equaled Lumos Pharma'saverage media sentiment score.
Qilian International Holding Group has a net margin of 0.00% compared to Lumos Pharma's net margin of -1,659.39%. Qilian International Holding Group's return on equity of 0.00% beat Lumos Pharma's return on equity.
Qilian International Holding Group has higher revenue and earnings than Lumos Pharma.
Qilian International Holding Group has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Lumos Pharma has a consensus target price of $18.00, indicating a potential upside of 490.16%. Given Lumos Pharma's higher probable upside, analysts plainly believe Lumos Pharma is more favorable than Qilian International Holding Group.
Lumos Pharma received 33 more outperform votes than Qilian International Holding Group when rated by MarketBeat users. However, 100.00% of users gave Qilian International Holding Group an outperform vote while only 77.27% of users gave Lumos Pharma an outperform vote.
34.0% of Lumos Pharma shares are owned by institutional investors. 58.7% of Qilian International Holding Group shares are owned by insiders. Comparatively, 25.4% of Lumos Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Qilian International Holding Group beats Lumos Pharma on 9 of the 14 factors compared between the two stocks.
Get Qilian International Holding Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for QLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Qilian International Holding Group Competitors List
Related Companies and Tools
